VRTX reports 7-day monotherapy data on ALS-2220, one of the two HCV nukes licensed from Alios BioPharma in 2011
ALS-2220 is a purine nuke so safety is an ongoing concern. Positive efficacy data from the pyrimidine ALS-2158 would be exciting for VRTX. Suggesting they will partner the drug with Incivek (in GT1) unfortunately will make it hard to take their HCV program seriously.
Market Data 
Markets 
AI
